everolimus (Afinitor)
Jump to navigation
Jump to search
Indications
- pharmaceutical agent used in drug-eluting stent
- chemotherapy for advanced kidney cancer
- hormone-receptor positive breast cancer
- for use in combination with Aromasin (exemestane) for treatment of postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer[3][6]
- recurrent endometrial cancer, in combination with letrozole[8]
- islet cell tumor[4]
- tuberous sclerosis
- prevention of renal graft rejection
- cardiac transplantation
- liver transplantation[4]
Dosage
Storage
- store in orginal container
- must be protected from light & moisture[5]
Adverse effects
- proteinuria[7]
- anemia, leukopenia[7]
- dysplipidemia[7]
- new-onset diabetes mellitus[7]
- mouth ulcers, infections, rash, fatigue, diarrhea, anorexia
- more common in elderly[3]
Laboratory
Mechanism of action
- antiproliferative agent
- reduces intimal hyperplasia
- mTOR inhibitor
More general terms
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB et al; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel- eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18430909
Patel MR, Holmes DR Jr. Next-generation drug-eluting stents: a spirited step forward or more of the same. JAMA. 2008 Apr 23;299(16):1952-3. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18430915 - ↑ Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 3.2 FDA News Release: July 20, 2012 FDA approves Afinitor for advanced breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312965.htm
- ↑ 4.0 4.1 4.2 Deprecated Reference
- ↑ 5.0 5.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 6.0 6.1 Baselga J, Campone M, Piccart M et al Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22149876
- ↑ 7.0 7.1 7.2 7.3 7.4 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 8.0 8.1 Bankhead C. Recurrent Endometrial Ca Responds to mTOR Drug. Responses in half of patients with no prior chemotherapy. MedPage Today. March 25, 2018 https://www.medpagetoday.com/meetingcoverage/sgo/71982
Slomovitz B, et al GOG 3007, a randomized phase II trial of everolimus and letrozole or hormonal therapy (medroxyprogesterone/tamoxifen) in women with advanced, persistent, or recurrent endometrial carcinoma: A GOG Foundation study. Society of Gynecologic Oncology (SGO) 2018;Abstract 1.